CRGX insider filings
CARGO Therapeutics, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2025-08-19. Screen CRGX transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for CRGX between 2026-07-10 and 2026-10-08. The table below lists the most recent filings on record.
Recent insider filings — CARGO Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2025-08-19 | 4 | Viswanadhan Krishnan — Director | Disposition to issuer (D): 3,173 (derivative) · Disposition to issuer (D): 25,000 (derivative) | EDGAR |
| 2025-08-19 | 4 | Radhakrishnan Anup — See Remarks | Code (U): 57,345 @ $4.38 · Disposition to issuer (D): 63,436 @ $4.38 · Disposition to issuer (D): 14,679 (derivative) | EDGAR |
| 2025-08-19 | 4 | Bassan Abraham — Director | Disposition to issuer (D): 25,000 (derivative) | EDGAR |
| 2025-08-19 | 4 | Huber Reid M — Director | Disposition to issuer (D): 25,000 (derivative) | EDGAR |
| 2025-08-19 | 4 | Lubner David Charles — Director | Disposition to issuer (D): 25,000 (derivative) | EDGAR |
| 2025-08-19 | 4 | Orwin John A — Director | Disposition to issuer (D): 15,865 (derivative) · Disposition to issuer (D): 25,000 (derivative) | EDGAR |
| 2025-08-19 | 4 | Dhingra Kapil — Director | Disposition to issuer (D): 25,000 (derivative) | EDGAR |
| 2025-08-19 | 4 | Henderson Jane — Director | Disposition to issuer (D): 25,000 (derivative) | EDGAR |
| 2025-07-03 | 4 | Radhakrishnan Anup — See Remarks | Sale (S): 1,632 @ $4.18 | EDGAR |
| 2025-06-23 | 4 | Viswanadhan Krishnan — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | Bassan Abraham — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | Huber Reid M — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | Lubner David Charles — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | Orwin John A — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | Dhingra Kapil — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | Henderson Jane — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-05-16 | 4 | Radhakrishnan Anup — See Remarks | Sale (S): 27,404 @ $3.84 | EDGAR |
| 2025-05-14 | 4 | Radhakrishnan Anup — See Remarks | Grant/award (A): 72,500 @ $0 | EDGAR |
| 2025-04-08 | 4 | Radhakrishnan Anup — See Remarks | Sale (S): 1,629 @ $4.00 | EDGAR |
| 2025-03-18 | 4 | Radhakrishnan Anup — See Remarks | Grant/award (A): 72,500 @ $0 | EDGAR |
| 2025-03-18 | 4 | Laport Ginna — Chief Medical Officer | Grant/award (A): 50,000 @ $0 | EDGAR |
| 2025-03-18 | 4 | Chapman Gina — President & CEO, Director | Grant/award (A): 200,000 @ $0 | EDGAR |
| 2025-03-18 | 4 | Gadam Shishir — Chief Technical Officer | Grant/award (A): 60,000 @ $0 | EDGAR |
| 2024-11-15 | 4 | Radhakrishnan Anup — See Remarks | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2024-09-20 | 4 | Chapman Gina — President & CEO, Director | Option exercise (M): 7,166 @ $5.03 · Sale (S): 7,166 @ $25.09 · Option exercise (M): 2,975 @ $5.03 · Sale (S): 2,975 @ $25.03 · Option exercise (M): 7,166 (derivative) @ $0 · Option exercise (M): 2,975 (derivative) @ $0 | EDGAR |
| 2024-09-20 | 4 | Radhakrishnan Anup — Chief Financial Officer | Option exercise (M): 1,600 @ $5.03 · Sale (S): 1,600 @ $25.28 · Option exercise (M): 1,600 (derivative) @ $0 | EDGAR |
| 2024-06-06 | 4 | Viswanadhan Krishnan — Director | Grant/award (A): 23,742 (derivative) @ $0 | EDGAR |
| 2024-06-06 | 4 | Bassan Abraham — Director | Grant/award (A): 23,742 (derivative) @ $0 | EDGAR |
| 2024-06-06 | 4 | Huber Reid M — Director | Grant/award (A): 23,742 (derivative) @ $0 | EDGAR |
| 2024-06-06 | 4 | Lubner David Charles — Director | Grant/award (A): 23,742 (derivative) @ $0 | EDGAR |
| 2024-06-06 | 4 | Orwin John A — Director | Grant/award (A): 23,742 (derivative) @ $0 | EDGAR |
| 2024-06-06 | 4 | Dhingra Kapil — Director | Grant/award (A): 11,871 (derivative) @ $0 | EDGAR |
| 2024-06-06 | 4 | Henderson Jane — Director | Grant/award (A): 19,785 (derivative) @ $0 · Grant/award (A): 39,402 (derivative) @ $0 | EDGAR |
| 2024-06-03 | 4 | Samsara BioCapital GP, LLC — 10% owner Samsara BioCapital, L.P. — 10% owner AKKARAJU SRINIVAS — 10% owner | Purchase (P): 294,000 @ $17 | EDGAR |
| 2024-04-17 | 4 | Dhingra Kapil — Director | Grant/award (A): 49,265 (derivative) @ $0 | EDGAR |
| 2024-03-04 | 4 | Laport Ginna — Chief Medical Officer | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2024-03-04 | 4 | Gadam Shishir — Chief Technical Officer | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2024-03-04 | 4 | Radhakrishnan Anup — Chief Financial Officer | Grant/award (A): 130,000 (derivative) @ $0 | EDGAR |
| 2024-03-04 | 4 | Chapman Gina — President & CEO, Director | Grant/award (A): 400,000 (derivative) @ $0 | EDGAR |
| 2024-01-16 | 4 | RTW INVESTMENTS, LP — 10% owner WONG RODERICK — 10% owner | Other (J): 1,842,499 | EDGAR |
| 2023-11-16 | 4 | Wellington Biomedical Innovation Master Investors (Cayman) II L.P. — 10% owner | Conversion (C): 737,000 · Conversion (C): 10,000,000 (derivative) @ $0 | EDGAR |
| 2023-11-16 | 4 | Samsara BioCapital GP, LLC — 10% owner Samsara BioCapital, L.P. — 10% owner AKKARAJU SRINIVAS — 10% owner | Conversion (C): 3,381,323 · Purchase (P): 666,666 @ $15 · Conversion (C): 663,300 (derivative) @ $0 · Conversion (C): 884,400 (derivative) @ $0 · Conversion (C): 1,833,623 (derivative) @ $0 | EDGAR |
| 2023-11-14 | 4 | Third Rock Ventures V, L.P. — 10% owner Third Rock Ventures GP V, LP — 10% owner TRV GP V, LLC — 10% owner Third Rock Ventures VI, L.P. — 10% owner Third Rock Ventures GP VI, L.P. — 10% owner TRV GP VI, LLC — 10% owner | Conversion (C): 1,737,216 · Conversion (C): 473,786 · Purchase (P): 1,333,333 @ $15 · Conversion (C): 23,571,429 (derivative) @ $0 · Conversion (C): 6,428,571 (derivative) @ $0 | EDGAR |
| 2023-11-14 | 4 | PERCEPTIVE ADVISORS LLC PERCEPTIVE LIFE SCIENCES MASTER FUND LTD Perceptive Xontogeny Venture Fund II, LP EDELMAN JOSEPH | Conversion (C): 2,579,502 · Purchase (P): 333,333 @ $15 · Purchase (P): 333,333 @ $15 · Conversion (C): 2,579,502 (derivative) | EDGAR |
| 2023-11-13 | 4 | Radhakrishnan Anup — Chief Financial Officer | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2023-11-13 | 4 | Viswanadhan Krishnan — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2023-11-13 | 4 | Bassan Abraham — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2023-11-13 | 4 | Huber Reid M — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2023-11-13 | 4 | Lubner David Charles — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2023-11-13 | 4 | Orwin John A — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — CARGO Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2025-08-19 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-07-08 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-07-02 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-06-20 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2025-03-18 | 8-K | ? 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-02-24 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-01-29 | 8-K | ? | EDGAR |
| 2025-01-10 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-11-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-08-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=CRGX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →